Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Amplifying Cash The executives: The Upsides and downsides of Various Ledgers - 2A few Exemplary Chinese Dishes, Which Are Famous Around the world
- 3Without evidence, CDC changes messaging on vaccines and autism
- 4Innovative Versatility: Examples of overcoming adversity from Entrepreneurs
- 5Voting begins in Uganda’s presidential election during internet shutdown and polling station delays
- Kona SUV: The Courageous Minimized That is Catching Hearts Around the world
- Higher cost, worse coverage: Affordable Care Act enrollees say expiring subsidies will hit them hard
- A Time of Careful Eating: Individual Tests in Nourishment
- Apollo vs. Artemis: What to know about NASA's return to the moon
- Getting ready for a Mechanized World: 10 Positions That computer based intelligence Could Dominate
- Artemis II's moon-bound astronauts capture Earth's brilliant blue beauty as they leave it behind
- The Most Astonishing Arising Advancements to Watch
- New method spots signs of Earth's primordial life in ancient rocks
- More parents refusing vitamin K shots for newborns, study finds
